Drugs Controller General of India nod for Covaxin phase 3 trials
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3)
Hyderabad: Covaxin, the Covid-19 vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) has been given approval for the third phase of clinical trials.
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad.
The DCGI granted permission to initiate Phase I & II human clinical trials in June this year, after the company submitted results generated from pre-clinical studies, demonstrating safety and immune response.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
